Revvity reported robust performance in its diagnostics segment during 2025, with immunodiagnostics outside China delivering 7% organic growth in Q4. The company’s Signals software offering was a standout, achieving high-teens year-over-year revenue growth and driving a 40% increase in SaaS annual recurring revenue. These results underline the successful integration of data analytics and cloud-based solutions into Revvity’s traditional instrumentation portfolio, positioning the company to capture additional market share in laboratory informatics and digital diagnostics.

In the fourth quarter, Revvity posted adjusted earnings of $1.70 per share, up 19.7% year over year and exceeding consensus by 10 basis points. Fourth-quarter revenue of $772 million was up 6% (4% organic), outperforming analysts’ estimates. Management issued 2026 guidance calling for adjusted EPS of $5.35–$5.45 (versus consensus of $5.32) and full-year sales of $2.96–$2.99 billion (versus consensus of $2.93 billion), implying mid-single-digit overall growth and 2–3% organic expansion driven by continued strength in non-China markets and ongoing portfolio transformation.

Revvity repurchased over $800 million of its own shares in 2025, reducing the share count by approximately 8.5 million and reinforcing its commitment to shareholder returns. While immunodiagnostics in China remains a drag on growth, the company has secured renewed NIH funding for key reagent platforms and is expanding partnerships with pharmaceutical companies for companion diagnostics. With a streamlined cost structure and growing software-driven recurring revenue, Revvity expects to leverage its enhanced R&D capabilities to deliver differentiated results over the next several years.